How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story

Eli Lilly recently reported exploratory Phase 3b data from the TOGETHER-PsO trial showing that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight altered far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings highlight a potential immunometabolic link between psoriasis and obesity, suggesting Lilly could unlock new treatment approaches by pairing its immunology and...